Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002495 · ClinicalTrials.gov registry record · Phase 3
SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 348
- Enrollment target
NCT00002495: Completed Phase 3 study, sponsored by SWOG Cancer Research Network.
NCT00002495 is a Phase 3 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 348 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002495, a Phase 3 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 348 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without doxorubicin and vinblastine in treating patients with stage I or stage II Hodgkin's disease.
Interventions
- DRUG vinblastine
- DRUG doxorubicin hydrochloride
- RADIATION standard subtotal nodal irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 1992-09 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
What the finished NCT00002495 record still lists
NCT00002495 is an interventional study that assigns participants to a tested intervention. The registered 348 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 3 interventions - of which vinblastine is the first listed.
NCT00002495 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002495 about?
NCT00002495 is a clinical study titled "SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without doxo...
What is the current status of trial NCT00002495?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 348 participants. The study started on 1992-09. Estimated completion is 2014-04.
What interventions are being tested in trial NCT00002495?
The interventions under investigation include: vinblastine (DRUG), doxorubicin hydrochloride (DRUG), standard subtotal nodal irradiation (RADIATION).
Who is sponsoring clinical trial NCT00002495?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002495's enrollment target sits among peer trials
348 1045th of 2000 higher than 953 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041479 · 348 participants · Phase 3
Biomarker-guided rTMS for Treatment Resistant Depression
- NCT04530565 · 348 participants · Phase 3
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
- NCT05428735 · 348 participants · NA
The DRAGON 2 Trial
- NCT05787379 · 348 participants · NA
Care for Veterans Post-COVID-19
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia